Daiichi Sankyo Company (4568) Q4 2026 earnings summary

Executive summary

• FY2025 revenue rose 12.6% year-on-year to JPY 2,123.0 billion, driven by strong oncology sales, especially ENHERTU and DATROWAY, and favorable foreign exchange effects.

• Core operating profit increased 15.1% to JPY 360.0 billion, but operating profit fell 31.0% to JPY 229.1 billion due to significant one-time expenses, including CMO compensation and impairment losses.

• Profit attributable to owners declined 12.1% to JPY 259.9 billion.

• Major R&D progress in antibody-drug conjugates (ADCs), with multiple regulatory approvals and clinical milestones for ENHERTU and DATROWAY.

• The sixth five-year business plan targets revenue over JPY 3 trillion and operating profit above JPY 600 billion by FY 2030, focusing on oncology and new drug discovery technologies.

Financial highlights

• Revenue: JPY 2,123.0 billion (+12.6% YoY); core operating profit: JPY 360.0 billion (+15.1% YoY); operating profit: JPY 229.1 billion (-31.0% YoY).

• Dividend per share increased by JPY 18 to JPY 78 for FY2025, with a forecast of JPY 100 for FY2026.

• Share repurchase of JPY 91.8 billion completed, with all shares to be canceled.

• Cash and cash equivalents at year-end: JPY 489.0 billion, down from JPY 639.8 billion.

• Profit attributable to owners: JPY 259.9 billion (-12.1% YoY); basic EPS: JPY 140.44.

Outlook and guidance

• FY2026 revenue forecasted to rise 7.4% to JPY 2,280.0 billion, with core operating profit projected at JPY 360.0 billion and operating profit up 37.5% to JPY 315.0 billion.

• Dividend planned to increase to JPY 100 per share for FY2026, with a progressive policy and DOE benchmark of 10%+.

• The five-year business plan targets revenue over JPY 3 trillion, operating profit above JPY 600 billion, and EPS above JPY 260 by FY2030, focusing on oncology and breakthrough technologies.

• Oncology revenue targeted at over JPY 2.3 trillion by FY2030.